Skip to main
ATXS
ATXS logo

Astria Therapeutics (ATXS) Stock Forecast & Price Target

Astria Therapeutics (ATXS) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 17%
Buy 50%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Astria Therapeutics Inc. demonstrates a positive outlook due to the favorable tolerance profile of its product candidates, particularly STAR-0310, which shows no adverse events related to antibody-dependent cellular cytotoxicity, indicating potential for improved efficacy over existing treatments. Additionally, the anticipated synergies from a merger with BioCryst are projected to enhance operational profitability from the first full year of revenue, thereby enriching Astria's financial performance and market position. The large commercial opportunity coupled with expected strategic growth initiatives positions Astria favorably for stakeholders, supported by a robust pipeline and significant news flow ahead.

Bears say

The financial outlook for Astria Therapeutics Inc is tempered by concerns regarding the potential for failed or inconclusive clinical trials that could hinder the development of its key product candidates, STAR-0215 and STAR-0310. Additionally, the company's ability to secure adequate funding is critical for progressing these drugs through the development pathway, and any shortfall in this area could significantly impact its financial stability. The risks associated with not meeting clinical milestones and the uncertain valuation, particularly in the context of potential acquisitions and competition, contribute to a cautious view on the company's stock performance.

Astria Therapeutics (ATXS) has been analyzed by 6 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 50% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Astria Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Astria Therapeutics (ATXS) Forecast

Analysts have given Astria Therapeutics (ATXS) a Buy based on their latest research and market trends.

According to 6 analysts, Astria Therapeutics (ATXS) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Astria Therapeutics (ATXS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.